Mississauga, Ontario (PRWEB) June 18, 2013
Inflamax Research Inc., a full service CRO specializing in Proof of Concept and Phase I-IV clinical trials, announced today that they will have a strategic alliance with Northern Air Environmental Technologies (NAET), a specialty air conditioning & environmental control company, for the deployment, monitoring, and servicing of mobile Environmental Exposure Chambers (EECs) used in Allergy, Asthma, and Ocular clinical trials.
Inflamax Research has proprietary Next Generation Environmental Exposure Chamber technology and is a world leader in allergy and asthma research. Mobile EECs (mEEC™), a groundbreaking advancement developed by Inflamax Research, allow for the conduct of multi-center allergy and ocular clinical trials and show great promise in furthering allergy and asthma research by allowing study sites to be set up at targeted locations with a high prevalence of specific allergies, rather than having patients commute to a fixed EEC site. Northern Air will work exclusively with Inflamax Research to support mEEC™ multicenter clinical trials in the area of facility and mEEC™ design, construction, and maintenance.
This strategic partnership between Inflamax Research and Northern Air will expedite trial operationalization by contracting the oversight of custom built environmental control units (ECU) and air handling systems to a sole vendor. Northern Air is involved from point of conceptual design to remote deployment, and on-site validation.
Inflamax Research will create the allergy models and Northern Air Environmental Technologies Inc. will custom-build the ECUs and supervise the air handling systems in Inflamax Research mEEC™. By having Northern Air as an exclusive vendor, Inflamax can focus on conducting the trials while being assured that the environmental control systems are being overseen by industry experts.
“I am pleased to have Northern Air partner with Inflamax Research to provide the best in Environmental Control Systems and importantly to keep them in top operation at all times,” says Dr. Salapatek, President and CSO Inflamax Research. “We have worked together on many projects in the past with Northern Air and are delighted to work with them again. This alliance allows Inflamax Research to continue to provide the best service possible in quality EEC clinical research”.
Brian Barney, President of Northern Air, echoed this positive outlook on the partnership, “Formalizing our relationship to become exclusive partners with Inflamax is the result of Inflamax and Northern Air Principals working together over many years. Inflamax is an innovator in clinical research and EEC technologies and Northern Air is a world leader in environmental control systems. Together, our companies will continue to lead further advancements.”
About Inflamax Research Inc.:
Inflamax conducts single and multi-centre Environmental Exposure Chamber (EEC) and field studies. In addition to Inflamax’s mobile EEC technology (mEEC™) systems which can be positioned globally, Inflamax has six fixed EECs, ranging in patient capacity from 25 to 100 patients at their headquarters in Toronto, Canada. Inflamax’s EECs have been validated for a variety of allergens and environmental conditions including ragweed, grass, dust mite, and tree allergens, and non-allergic provocateurs such as thermal shifts, fragrance, ozone and low humidity conditions such as those utilized in the study of dry eye syndrome.
About Northern Air Environmental Technologies Inc.:
Northern Air Environmental Technologies Inc. is a full service provider of turn-key environmental systems. Northern Air’s range of skills will take a project from raw concept, through detailed design, and construction, and provide clients with a single-sourced solution that truly achieves the overall performance goals of the system. The approach is innovative, utilizing leading edge technology, controls and data-logging, and is based upon over four decades of experience in all aspects of the commercial and industrial sectors.
Read the full story at http://www.prweb.com/releases/2013/6/prweb10843613.htm.
Copyright©2012 Vocus, Inc.
All rights reserved